Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Total Non-Current Liabilities (2020 - 2025)

Rapid Micro Biosystems' Total Non-Current Liabilities history spans 6 years, with the latest figure at $41.2 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 83.17% to $41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.2 million, a 83.17% increase, with the full-year FY2025 number at $41.2 million, up 83.17% from a year prior.
  • Total Non-Current Liabilities hit $41.2 million in Q4 2025 for Rapid Micro Biosystems, up from $39.7 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for RPID hit a ceiling of $135.5 million in Q1 2021 and a floor of $18.4 million in Q3 2021.
  • Historically, Total Non-Current Liabilities has averaged $30.2 million across 5 years, with a median of $22.2 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 83.58% in 2022 and later soared 87.51% in 2025.
  • Tracing RPID's Total Non-Current Liabilities over 5 years: stood at $19.0 million in 2021, then soared by 38.32% to $26.3 million in 2022, then fell by 4.01% to $25.2 million in 2023, then dropped by 10.64% to $22.5 million in 2024, then skyrocketed by 83.17% to $41.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RPID at $41.2 million in Q4 2025, $39.7 million in Q3 2025, and $20.7 million in Q2 2025.